| Recommendations | Grade | Level of evidence | Key references | |
|---|---|---|---|---|
|
| ||||
| 4.3 | Treat all patients with CLTI with an antiplatelet agent. | 1 (Strong) | A (High) | Antithrombotic Trialists’ Collaboration,33 2002 Antithrombotic Trialists’ Collaboration,34 2009 |
| 4.4 | Consider clopidogrel as the single antiplatelet agent of choice in patients with CLTI. | 2 (Weak) | B (Moderate) | CAPRIE,35 1996 Hiatt,36 2017 |
| 4.5 | Consider low-dose aspirin and rivaroxaban, 2.5 mg twice daily, to reduce adverse cardiovascular events and lower extremity ischemic events in patients with CLTI. | 2 (Weak) | B (Moderate) | Anand,37 2018 |
| 4.6 | Do not use systemic vitamin K antagonists for the treatment of lower extremity atherosclerosis in patients with CLTI. | 1 (Strong) | B (Moderate) | Anand,38 2007 |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.